S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
66,000% upside on tiny biotech? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
66,000% upside on tiny biotech? (Ad)
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
66,000% upside on tiny biotech? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
66,000% upside on tiny biotech? (Ad)
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
66,000% upside on tiny biotech? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
66,000% upside on tiny biotech? (Ad)
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
66,000% upside on tiny biotech? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
66,000% upside on tiny biotech? (Ad)
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
Twitter executive responsible for content safety resigns after Elon Musk criticism
NASDAQ:VNDA

Vanda Pharmaceuticals (VNDA) Stock Forecast, Price & News

$6.06
+0.16 (+2.71%)
(As of 06/2/2023 ET)
Compare
Today's Range
$5.90
$6.08
50-Day Range
$5.90
$6.95
52-Week Range
$5.75
$11.90
Volume
658,681 shs
Average Volume
517,848 shs
Market Capitalization
$348.09 million
P/E Ratio
20.90
Dividend Yield
N/A
Price Target
N/A

Vanda Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
5.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.77
Upright™ Environmental Score
News Sentiment
0.37mentions of Vanda Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.44) to ($0.95) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

729th out of 983 stocks

Pharmaceutical Preparations Industry

366th out of 486 stocks


VNDA stock logo

About Vanda Pharmaceuticals (NASDAQ:VNDA) Stock

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Receive VNDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VNDA Stock News Headlines

How A.I. Could Make Most 21st Century Diseases EXTINCT
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
How A.I. Could Make Most 21st Century Diseases EXTINCT
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
4 Best Biotech Stocks According to POWR Ratings
Q1 2023 Vanda Pharmaceuticals Inc Earnings Call
Novartis to Market Vanda's Fanapt Drug
Vanda Pharmaceuticals Inc. (VNDA)
Vanda Pharmaceuticals wins lawsuit against FDA
Vanda Prevails in Jet Lag Litigation Against the FDA
See More Headlines

VNDA Price History

VNDA Company Calendar

Last Earnings
11/03/2021
Today
6/03/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:VNDA
CUSIP
92165910
Employees
278
Year Founded
2002

Profitability

Net Income
$6.28 million
Pretax Margin
9.50%

Debt

Sales & Book Value

Annual Sales
$254.38 million
Cash Flow
$0.11 per share
Book Value
$9.33 per share

Miscellaneous

Free Float
53,423,000
Market Cap
$348.09 million
Optionable
Optionable
Beta
0.68

Social Links


Key Executives

  • Mihael Hristos PolymeropoulosMihael Hristos Polymeropoulos
    Chairman, President & Chief Executive Officer
  • Kevin Moran
    Chief Financial Officer, Treasurer & SVP
  • Tim Williams
    Secretary, Senior VP & General Counsel
  • Kim WijkstromKim Wijkstrom
    Senior Vice President & Chief Marketing Officer
  • Gunther Birznieks
    Senior Vice President-Business Development













VNDA Stock - Frequently Asked Questions

How have VNDA shares performed in 2023?

Vanda Pharmaceuticals' stock was trading at $7.39 at the beginning of the year. Since then, VNDA stock has decreased by 18.0% and is now trading at $6.06.
View the best growth stocks for 2023 here
.

When is Vanda Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our VNDA earnings forecast
.

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) issued its earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.20 by $0.06. The biopharmaceutical company earned $70.10 million during the quarter, compared to analyst estimates of $73.50 million. Vanda Pharmaceuticals had a trailing twelve-month return on equity of 3.06% and a net margin of 6.22%. During the same period in the prior year, the business posted $0.11 earnings per share.

What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO?

12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Vanda Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX).

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

Who are Vanda Pharmaceuticals' major shareholders?

Vanda Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (17.58%), State Street Corp (7.92%), Renaissance Technologies LLC (5.11%), Dimensional Fund Advisors LP (4.85%), Bank of America Corp DE (2.84%) and Pictet Asset Management SA (2.12%). Insiders that own company stock include Aranthan Jones II, Gunther Birznieks, Joakim Wijkstrom, Kevin Patrick Moran, Melissa Young, Mihael Hristos Polymeropoulos, Phaedra Chrousos, Richard W Dugan, Stephen Ray Mitchell, Thomas Watkins and Timothy Williams.
View institutional ownership trends
.

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vanda Pharmaceuticals' stock price today?

One share of VNDA stock can currently be purchased for approximately $6.06.

How much money does Vanda Pharmaceuticals make?

Vanda Pharmaceuticals (NASDAQ:VNDA) has a market capitalization of $348.09 million and generates $254.38 million in revenue each year. The biopharmaceutical company earns $6.28 million in net income (profit) each year or $0.29 on an earnings per share basis.

How many employees does Vanda Pharmaceuticals have?

The company employs 278 workers across the globe.

How can I contact Vanda Pharmaceuticals?

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. The official website for the company is www.vandapharma.com. The biopharmaceutical company can be reached via phone at (202) 734-3400, via email at pr@vandapharma.com, or via fax at 202-296-1450.

This page (NASDAQ:VNDA) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -